EyePoint Pharmaceuticals Inc
EYPT10.040USD
+0.330+3.40%
交易中 （美東）報價延遲15分鐘
690.87M總市值
虧損本益比TTM
關於 EyePoint Pharmaceuticals Inc 公司
EyePoint Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化用於治療眼部疾病的眼科產品。該公司的產品線利用其 Durasert 技術 (Durasert) 進行持續眼內藥物輸送，包括輸送 EYP-1901，這是一種針對抗血管內皮生長因子 (anti-VEGF) 介導的視網膜疾病的試驗性持續輸送治療。其其他產品線計劃包括 EYP-2301，一種有前途的 TIE-2 激動劑，razuprotafib，以 Durasert E 配製，可能改善嚴重視網膜疾病的結果。EYP-1901 目前處於 2 期臨牀試驗階段，作爲溼性老年性黃斑變性 (wet AMD)、非增生性糖尿病視網膜病變 (NPDR) 和糖尿病性黃斑水腫 (DME) 的持續輸送治療。該公司的其他產品包括 YUTIQ 和 DEXYCU。
公司簡介
公司代碼EYPT
公司名稱EyePoint Pharmaceuticals Inc
上市日期Jan 27, 2005
CEODr. Jay S. Duker, M.D.
員工數量165
證券類型Ordinary Share
年結日Jan 27
公司地址480 Pleasant Street, Suite C400
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02472
電話16179265000
網址https://eyepointpharma.com/
公司代碼EYPT
上市日期Jan 27, 2005
CEODr. Jay S. Duker, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
41.78K
--
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
YUTIQ
3.10M
7.16%
地區USD
名稱
營收
佔比
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
業務
地區
業務USD
名稱
營收
佔比
YUTIQ
3.10M
7.16%
股東統計
更新時間: 7月25日 週五
更新時間: 7月25日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Cormorant Asset Management, LP
12.10%
Suvretta Capital Management, LLC
9.89%
Adage Capital Management, L.P.
9.01%
BlackRock Institutional Trust Company, N.A.
7.19%
Franklin Advisers, Inc.
5.99%
Other
55.83%
持股股東
持股股東
佔比
Cormorant Asset Management, LP
12.10%
Suvretta Capital Management, LLC
9.89%
Adage Capital Management, L.P.
9.01%
BlackRock Institutional Trust Company, N.A.
7.19%
Franklin Advisers, Inc.
5.99%
Other
55.83%
股東類型
持股股東
佔比
Hedge Fund
39.71%
Investment Advisor
28.58%
Investment Advisor/Hedge Fund
22.88%
Venture Capital
7.91%
Research Firm
5.09%
Private Equity
4.39%
Individual Investor
3.52%
Bank and Trust
1.52%
Pension Fund
0.40%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
384
78.48M
114.05%
-10.35M
2025Q1
386
76.27M
110.90%
-11.90M
2024Q4
373
75.75M
111.39%
+202.32K
2024Q3
358
60.55M
112.89%
-8.01M
2024Q2
345
60.80M
116.35%
-2.75M
2024Q1
328
57.32M
114.97%
+528.95K
2023Q4
282
52.72M
108.16%
+11.49M
2023Q3
239
37.39M
106.16%
-1.26M
2023Q2
224
35.30M
102.90%
-4.83M
2023Q1
220
33.02M
96.37%
-5.12M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Cormorant Asset Management, LP
8.32M
12.1%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
6.80M
9.89%
+21.00K
+0.31%
Mar 31, 2025
Adage Capital Management, L.P.
6.20M
9.01%
+450.00K
+7.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
7.19%
+206.82K
+4.36%
Mar 31, 2025
Franklin Advisers, Inc.
4.12M
5.99%
+9.56K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
3.82M
5.55%
+31.14K
+0.82%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
3.71M
5.39%
+2.50K
+0.07%
Mar 31, 2025
TCG Crossover Management, LLC
3.57M
5.19%
--
--
Mar 31, 2025
RA Capital Management, LP
3.18M
4.62%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.29M
3.32%
-180.78K
-7.33%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
SPDR S&P Pharmaceuticals ETF
0.79%
Simplify Health Care ETF
0.57%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.56%
Federated Hermes MDT Small Cap Core ETF
0.37%
iShares Micro-Cap ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Russell 2000 Value ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.96%
SPDR S&P Pharmaceuticals ETF
佔比0.79%
Simplify Health Care ETF
佔比0.57%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.56%
Federated Hermes MDT Small Cap Core ETF
佔比0.37%
iShares Micro-Cap ETF
佔比0.13%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
Invesco Nasdaq Biotechnology ETF
佔比0.07%
iShares Russell 2000 Value ETF
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
公告日期
類型
比率
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
